Alexion Pharmaceuticals, Inc. (ALXN) Holdings Trimmed by Granite Investment Partners LLC

Granite Investment Partners LLC trimmed its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 6.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,369 shares of the biopharmaceutical company’s stock after selling 2,917 shares during the quarter. Granite Investment Partners LLC’s holdings in Alexion Pharmaceuticals were worth $6,168,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ALXN. Jennison Associates LLC boosted its stake in Alexion Pharmaceuticals by 43.1% in the 3rd quarter. Jennison Associates LLC now owns 8,627,536 shares of the biopharmaceutical company’s stock worth $1,199,314,000 after purchasing an additional 2,599,414 shares during the period. Iridian Asset Management LLC CT boosted its stake in Alexion Pharmaceuticals by 14,950.7% in the 2nd quarter. Iridian Asset Management LLC CT now owns 1,496,192 shares of the biopharmaceutical company’s stock worth $185,752,000 after purchasing an additional 1,486,251 shares during the period. American Century Companies Inc. boosted its position in shares of Alexion Pharmaceuticals by 164.2% during the 3rd quarter. American Century Companies Inc. now owns 1,904,296 shares of the biopharmaceutical company’s stock valued at $264,716,000 after acquiring an additional 1,183,476 shares during the last quarter. Advisors Asset Management Inc. boosted its position in shares of Alexion Pharmaceuticals by 7,677.7% during the 2nd quarter. Advisors Asset Management Inc. now owns 1,155,454 shares of the biopharmaceutical company’s stock valued at $2,288,000 after acquiring an additional 1,140,598 shares during the last quarter. Finally, Sound Shore Management Inc. CT bought a new position in shares of Alexion Pharmaceuticals during the 2nd quarter valued at approximately $134,590,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

ALXN stock opened at $118.62 on Monday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.74 and a current ratio of 3.16. Alexion Pharmaceuticals, Inc. has a twelve month low of $102.10 and a twelve month high of $140.77. The firm has a market capitalization of $26.46 billion, a price-to-earnings ratio of 22.99, a price-to-earnings-growth ratio of 1.02 and a beta of 0.99.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.74 by $0.28. Alexion Pharmaceuticals had a return on equity of 16.60% and a net margin of 3.90%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter last year, the firm posted $1.44 earnings per share. The business’s revenue was up 19.5% compared to the same quarter last year. Sell-side analysts predict that Alexion Pharmaceuticals, Inc. will post 6.82 earnings per share for the current fiscal year.

ALXN has been the subject of a number of research reports. Zacks Investment Researchdowngraded Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 13th. Barclays increased their target price on Alexion Pharmaceuticals to $175.00 and gave the company an “overweight” rating in a research report on Friday, September 28th. Credit Suisse Group set a $156.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, September 25th. BidaskClub upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, September 29th. Finally, Stifel Nicolaus downgraded Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their target price for the company from $154.00 to $130.00 in a research report on Tuesday, August 7th. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $161.50.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.